Canada markets open in 2 minutes

BriaCell Therapeutics Corp. (BCT.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
1.9700+0.0800 (+4.23%)
At close: 01:55PM EDT
Full screen
Previous Close1.8900
Open1.9600
Bid1.9800 x N/A
Ask2.0300 x N/A
Day's Range1.9600 - 2.0400
52 Week Range1.7100 - 10.1982
Volume600
Avg. Volume10,296
Market Cap36.021M
Beta (5Y Monthly)1.84
PE Ratio (TTM)N/A
EPS (TTM)-1.0900
Earnings DateJun 14, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    BriaCell Presents Clinical Efficacy Data at ASCO 2024

    BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literatureBria-IMT™ PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Drug Conjugate (ADC) resistant patientsTherapy well-tolerated with no Bria-IMT™ related discontinuationsClinical data highlight significant potential of Bria-IMT™ in advanced metastatic breast cancerSuperiority of selected Phase 3 regimen and formulation confirmedOral presentation by Mayo Clinic Profe

  • GlobeNewswire

    BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic Breast Cancer

    PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces initiation of a first-in-human, Phase 1/2 study evaluating safety and efficacy of Bria-OTS™, BriaCell’s personalized off-the-shelf next generation immunotherapy, as monotherapy and in combination with PD-1 inhibitor ti

  • GlobeNewswire

    BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study

    Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer. PHILADELPHIA and VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces a clinical supply agreement with BeiGene, Ltd. (NASD